Corcept Therapeutics (CORT)
(Delayed Data from NSDQ)
$42.95 USD
+0.70 (1.66%)
Updated Sep 23, 2024 04:00 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Income Statements
Fiscal Year end for Corcept Therapeutics Incorporated falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 482 | 402 | 366 | 354 | 306 |
Cost Of Goods | 6 | 5 | 5 | 6 | 6 |
Gross Profit | 476 | 396 | 361 | 348 | 301 |
Selling & Adminstrative & Depr. & Amort Expenses | 369 | 284 | 236 | 220 | 189 |
Income After Depreciation & Amortization | 107 | 113 | 124 | 128 | 112 |
Non-Operating Income | 17 | 4 | 1 | 3 | 5 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | 125 | 116 | 125 | 132 | 117 |
Income Taxes | 18 | 15 | 12 | 26 | 23 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 106 | 101 | 113 | 106 | 94 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 106 | 101 | 113 | 106 | 94 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 101 | 116 | 128 | 132 | 114 |
Depreciation & Amortization (Cash Flow) | -7 | 3 | 3 | 4 | 2 |
Income After Depreciation & Amortization | 107 | 113 | 124 | 128 | 112 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 111.74 | 115.97 | 125.96 | 124.19 | 122.57 |
Diluted EPS Before Non-Recurring Items | 0.94 | 0.87 | 0.89 | 0.85 | 0.77 |
Diluted Net EPS (GAAP) | 0.94 | 0.87 | 0.89 | 0.85 | 0.77 |
Fiscal Year end for Corcept Therapeutics Incorporated falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 163.80 | 146.81 | 135.41 | 123.60 | 117.72 |
Cost Of Goods | 2.52 | 2.54 | 1.88 | 1.65 | 1.57 |
Gross Profit | 161.27 | 144.27 | 133.53 | 121.96 | 116.14 |
SG&A, R&D, and Dept/Amort Expenses | 125.69 | 114.78 | 101.86 | 90.78 | 86.56 |
Income After SG&A, R&D, and Dept/Amort Expenses | 35.58 | 29.49 | 31.67 | 31.18 | 29.58 |
Non-Operating Income | 6.00 | 5.49 | 5.14 | 5.21 | 3.35 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | 41.60 | 34.99 | 36.81 | 36.39 | 32.93 |
Income Taxes | 6.11 | 7.23 | 5.45 | 5.01 | 5.40 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | 35.49 | 27.76 | 31.36 | 31.38 | 27.53 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | 35.49 | 27.76 | 31.36 | 31.38 | 27.53 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 111.24 | 109.92 | 110.89 | 111.10 | 109.59 |
Diluted EPS Before Non-Recurring Items | 0.32 | 0.25 | 0.28 | 0.28 | 0.25 |
Diluted Net EPS (GAAP) | 0.32 | 0.25 | 0.27 | 0.28 | 0.25 |